Kurs & Likviditet
|2023-03-24||Ordinarie utdelning REG1V 0.36 EUR|
|2022-04-11||Ordinarie utdelning REG1V 0.34 EUR|
|2021-03-18||Ordinarie utdelning REG1V 0.32 EUR|
|2020-06-09||Ordinarie utdelning REG1V 0.30 EUR|
|2019-03-21||Ordinarie utdelning REG1V 0.28 EUR|
|2018-03-21||Ordinarie utdelning REG1V 0.78 EUR|
|2017-03-23||Ordinarie utdelning REG1V 0.74 EUR|
|2016-03-16||Ordinarie utdelning REG1V 0.70 EUR|
|2015-03-20||Ordinarie utdelning REG1V 0.45 EUR|
|2014-03-21||Ordinarie utdelning REG1V 0.30 EUR|
|2013-12-11||Bonusutdelning REG1V 0.3|
|2013-12-09||Extra Bolagsstämma 2013|
|2013-08-02||Bonusutdelning REG1V 0.12|
|2013-03-28||Split REG1V 10:1|
|2013-03-22||Ordinarie utdelning REG1V 0.02 EUR|
|2012-03-29||Ordinarie utdelning REG1V 0.02 EUR|
|2011-04-01||Ordinarie utdelning REG1V 0.02 EUR|
|2010-04-09||Ordinarie utdelning REG1V 0.01 EUR|
|2009-04-16||Ordinarie utdelning REG1V 0.02 EUR|
|2008-04-03||Ordinarie utdelning REG1V 0.04 EUR|
|2007-04-09||Ordinarie utdelning REG1V 0.01 EUR|
|2006-03-31||Ordinarie utdelning REG1V 0.00 EUR|
|2005-04-01||Ordinarie utdelning REG1V 0.00 EUR|
|2004-03-29||Ordinarie utdelning REG1V 0.00 EUR|
|2003-03-24||Ordinarie utdelning REG1V 0.00 EUR|
|2002-04-15||Ordinarie utdelning REG1V 0.00 EUR|
|Lista||Large Cap Helsinki|
Revenio Group Corporation, Stock exchange release, February 1, 2023 at 8.00 a.m. (EET)
Changes to Revenio's organizational structure and Leadership Team
Revenio Group Corporation is renewing its organizational structure in order to support the company's growth. Over the past two years, Revenio has gone through a significant evolution from an equipment supplier to a global leader of comprehensive eye diagnostics solutions. The objective of the change in the organizational structure is to support the solution business and the increasingly stronger customer experience by centralizing the Products, Brand and Marketing as well as Sales into their own units. The Research and Product Development operations, which were previously decentralized, will also be brought together in a single unit to serve the Group's business operations centrally. In addition, a Strategy and Business Development unit will be established to support the company's strategic objectives, which will be responsible for clinical applications, strategic partnerships and thought leadership. The new organizational structure will enter into force on February 1, 2023.
“Our business is based on sustainable and profitable growth. With the new organizational model, we will support our growth and clarify the management and transparency of our strategic priorities. We used to operate in the equipment business but, as a result of the acquisitions, our business also covers software expertise. This requires a change of operating model. From the point of view of customer experience, it is important that we can offer our services and products by the same teams, using the same distribution channels in all of our markets,” emphasizes CEO Jouni Toijala.
Changes in the responsibilities of the Leadership Team
The new organizational structure will bring changes to the responsibilities of the Leadership Team and introduce one new member to the Leadership Team. Tomi Karvo, who was previously responsible for sales and marketing, takes full responsibility for the Products, Brand and Marketing unit’s operations. John Floyd has been appointed Vice President, Sales, and a member of the Leadership Team. He has long served as CEO of Revenio's subsidiary Icare USA Inc in the United States, where he was also responsible for sales. Kate Taylor, previously responsible for the Eye Care Solutions business, has been appointed Vice President of the new Strategy and Business Development unit.
Giuliano Barbaro, who has successfully led the Research and Product Development unit, has announced that he will take up new responsibilities outside the company and will continue in his position until the end of June, and he will ensure a controlled transfer of his tasks during the Spring. The search for the new Vice President for the Research and Product Development unit will be launched immediately.
“I warmly thank Giuliano for his outstanding and groundbreaking work for Revenio and wish him every success in the development of therapies for treatment of cancer diseases. At the same time, I warmly welcome John Floyd as a member of the Leadership Team. I also wish Kate Taylor, who will continue in a new role in the Leadership Team, every success. I am very pleased that we have found talented managers through internal transfers for these new important roles,” says Jouni Toijala.
Composition and responsibilities of the Revenio Group Leadership Team as of February 1, 2023:
- Jouni Toijala, CEO
- Giuliano Barbaro, Vice President, Research and Product Development until June 30, 2023
- John Floyd, Vice President, Sales – Member of the Leadership Team starting from February 1, 2023
- Heli Huopaniemi, Vice President, Quality
- Ari Isomäki, Vice President, Operations
- Tomi Karvo, Vice President, Products, Brand and Marketing
- Robin Pulkkinen, CFO
- Kate Taylor, Vice President, Strategy and Business Development
- Hanna Vuornos, Vice President, People and Culture
The change in the organizational model supports the implementation of the strategy. Revenio will update its strategy with the support of the new organization during the Spring.
The CV of John Floyd, who will start as a new member of Revenio’s Leadership Team on February 1, 2023, is attached to this release. The CVs of the current members of Revenio's Leadership Team can be found on Revenio's website at https://www.reveniogroup.fi/en/investors/corporate_governance/leadership_team
For further information, please contact
Jouni Toijala, CEO, tel. +358 50 484 0085
Revenio Group in brief
Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.
In 2021, the Group’s net sales totaled EUR 78.8 million, with an operating profit of EUR 22.1 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.